Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO - Concepedia

Concepedia

Publication | Open Access

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO

DOI Full Paper Access

102

Citations

36

References

2013

Year

Isabelle Ray‐Coquard, Laure Favier, B. Weber, C. Roemer-Bécuwe, Philippe Bougnoux, Michel Fabbro, Anne Floquet, Florence Joly, A. Plantade, D. Paraïso,

British Journal of Cancer

Abstract

Everolimus demonstrated efficacy and acceptable tolerability in patients with chemotherapy-refractory advanced or metastatic endometrial cancer. These results support the further development of phosphatidylinositol 3-kinase-targeted therapies in endometrial cancer.

References

	Year	Citations

Page 1